The TGFB3 antibody is a crucial tool for studying transforming growth factor-beta 3 (TGF-β3), a member of the TGF-β superfamily involved in regulating cell proliferation, differentiation, apoptosis, and immune responses. TGF-β3 shares structural and functional similarities with TGF-β1 and TGF-β2 but exhibits distinct roles in embryonic development, tissue repair, and disease processes. It is particularly associated with palatogenesis, cardiac morphogenesis, and wound healing. Dysregulation of TGF-β3 has been implicated in fibrosis, cancer progression, and congenital disorders like cleft palate.
TGFB3 antibodies are designed to detect and quantify TGF-β3 protein in biological samples through techniques such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA). These antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes of TGF-β3. Validation includes testing for cross-reactivity with other TGF-β isoforms to ensure specificity, as overlapping functions among isoforms can complicate interpretations.
Researchers use TGFB3 antibodies to explore its dual role in cancer—both as a tumor suppressor in early stages and a promoter of metastasis in advanced disease—as well as its therapeutic potential in regenerative medicine. Commercial antibodies often vary in reactivity across species (human, mouse, rat) and applications, requiring careful selection based on experimental needs. Understanding TGF-β3's context-dependent signaling via SMAD or non-SMAD pathways remains a key focus, driving demand for reliable detection tools.